4/7
08:50 am
otlk
Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by FDA
Medium
Report
Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by FDA
3/25
04:05 pm
otlk
Outlook Therapeutics Announces Closing of $5.0 Million Public Offering
Low
Report
Outlook Therapeutics Announces Closing of $5.0 Million Public Offering
3/24
07:00 am
otlk
Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering
High
Report
Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering
3/23
05:48 pm
otlk
Outlook Therapeutics Announces Proposed Public Offering [Yahoo! Finance]
High
Report
Outlook Therapeutics Announces Proposed Public Offering [Yahoo! Finance]
3/23
05:43 pm
otlk
Outlook Therapeutics launches public offering; shares down [Seeking Alpha]
High
Report
Outlook Therapeutics launches public offering; shares down [Seeking Alpha]
3/23
05:30 pm
otlk
Outlook Therapeutics Announces Proposed Public Offering
High
Report
Outlook Therapeutics Announces Proposed Public Offering
3/16
08:34 am
otlk
Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note [Yahoo! Finance]
High
Report
Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note [Yahoo! Finance]
3/16
08:05 am
otlk
Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note
High
Report
Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note
3/11
08:03 am
otlk
Oncobiologics (OTLK) had its price target lowered by Ascendiant Capital Markets from $10.00 to $6.00. They now have a "buy" rating on the stock.
Medium
Report
Oncobiologics (OTLK) had its price target lowered by Ascendiant Capital Markets from $10.00 to $6.00. They now have a "buy" rating on the stock.
3/5
04:57 pm
otlk
Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg) [Yahoo! Finance]
Medium
Report
Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg) [Yahoo! Finance]
3/5
04:15 pm
otlk
Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg)
Medium
Report
Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg)
2/19
09:00 am
otlk
Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA™ (bevacizumab gamma) in Switzerland
Low
Report
Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA™ (bevacizumab gamma) in Switzerland
2/18
08:13 am
otlk
Oncobiologics (NASDAQ:OTLK) had its "neutral" rating reaffirmed by analysts at HC Wainwright. They now have a $0.50 price target on the stock.
Medium
Report
Oncobiologics (NASDAQ:OTLK) had its "neutral" rating reaffirmed by analysts at HC Wainwright. They now have a $0.50 price target on the stock.
2/18
08:13 am
otlk
Oncobiologics (NASDAQ:OTLK) had its "neutral" rating reaffirmed by analysts at Chardan Capital. They now have a $1.00 price target on the stock.
Medium
Report
Oncobiologics (NASDAQ:OTLK) had its "neutral" rating reaffirmed by analysts at Chardan Capital. They now have a $1.00 price target on the stock.
2/17
08:05 am
otlk
Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
High
Report
Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
2/11
08:45 am
otlk
Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter
Medium
Report
Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter